FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281330> ?p ?o ?g. }

• W4379281330 endingPage "10587" @default.
• W4379281330 startingPage "10587" @default.
• W4379281330 abstract "10587 Background: About 5-10% of breast cancers (BC) are related to germline BRCA 1/2 pathogenic variants (PV). Several studies have demonstrated the effectiveness of PARP inhibitors (PARPi) in this population. However, BC patients with BRCA PVs remain a challenge to treat. In this report, we aim to characterize the clinical characteristics and outcome of a single institution cohort of advanced BC patients with a BRCA PV and who received PARPi therapy. Methods: Patients with BRCA 1/2 germline PVs who presented to the University of Texas MD Anderson Cancer Center Breast Medical Oncology clinics and were treated with PARPi between 2008-2022 as part of their treatment for metastatic or recurrent disease were included in the analysis. Variables included in this analysis included age at diagnosis, family history of BC and ovarian cancer, treatment details, tumor characteristics including histological type, receptor status and clinical outcome. Descriptive statistics, the Kaplan-Meier method, and The Cox proportional hazards regression model were used to report patient characteristics and outcomes. Progression free survival (PFS) was defined as the time from treatment initiation of PARPi to disease progression or death. Overall survival (OS) was defined as the time from treatment initiation of PARPi to death of any cause. Results: One hundred and seven patients were treated with PARPi. Median age at diagnosis was 38 years (23-73). Forty-eight (44.9%) and 59 (55.1%) patients had BRCA1 and BRCA2 mutations, respectively. Ninety-seven (90.7%) had invasive ductal carcinoma and 42 (39.3%) had triple negative BC. Nineteen (17.8%) patients were de novo metastatic BC (Stage IV). Sixty-two (57.9%) patients received one or more prior lines of chemotherapy before being treated with PARPi; 24 (22.4%) patients received prior platinum. In 91 patients evaluable for clinical response, the overall response rate (ORR) was 59.4% and the duration of response (DoR) was 7 months (2.1-96.2). In platinum-naïve patients ORR was 70.4% and DoR 7.4 months (2.1-96.2). Median PFS was 8.9 months (95% CI 6.3-10.3) and median OS 25.8 mo (95% CI 18.3-30.9). In univariate analysis, first-line PARPi use (p = 0.0274) and no previous use of platinum (p = 0.0121) were statistically significant for better PFS. Hormone receptor positive BC (p = 0.0105) was statistically significant for better OS. Conclusions: In this real-world single institution cohort of advanced BC patients with BRCA germline PVs who were treated with PARPi, the ORR and outcome of patients is similar to those reported in the previous clinical trials. Platinum naïve and patients who received PARPi as 1 st line therapy had a better ORR. Further studies of predictive markers of response and resistance as well as sequencing with platinums are needed to optimize the use of PARPi in this patient population." @default.
• W4379281330 created "2023-06-05" @default.
• W4379281330 creator A5005148722 @default.
• W4379281330 creator A5006094200 @default.
• W4379281330 creator A5015127974 @default.
• W4379281330 creator A5049589636 @default.
• W4379281330 creator A5053119598 @default.
• W4379281330 creator A5064168158 @default.
• W4379281330 date "2023-06-01" @default.
• W4379281330 modified "2023-10-18" @default.
• W4379281330 title "Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience." @default.
• W4379281330 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.10587" @default.
• W4379281330 hasPublicationYear "2023" @default.
• W4379281330 type Work @default.
• W4379281330 citedByCount "0" @default.
• W4379281330 crossrefType "journal-article" @default.
• W4379281330 hasAuthorship W4379281330A5005148722 @default.
• W4379281330 hasAuthorship W4379281330A5006094200 @default.
• W4379281330 hasAuthorship W4379281330A5015127974 @default.
• W4379281330 hasAuthorship W4379281330A5049589636 @default.
• W4379281330 hasAuthorship W4379281330A5053119598 @default.
• W4379281330 hasAuthorship W4379281330A5064168158 @default.
• W4379281330 hasConcept C104317684 @default.
• W4379281330 hasConcept C121608353 @default.
• W4379281330 hasConcept C126322002 @default.
• W4379281330 hasConcept C143998085 @default.
• W4379281330 hasConcept C182979987 @default.
• W4379281330 hasConcept C2779138821 @default.
• W4379281330 hasConcept C2780194787 @default.
• W4379281330 hasConcept C2780427987 @default.
• W4379281330 hasConcept C2781179581 @default.
• W4379281330 hasConcept C2908647359 @default.
• W4379281330 hasConcept C50382708 @default.
• W4379281330 hasConcept C530470458 @default.
• W4379281330 hasConcept C54355233 @default.
• W4379281330 hasConcept C71924100 @default.
• W4379281330 hasConcept C82381507 @default.
• W4379281330 hasConcept C86803240 @default.
• W4379281330 hasConcept C99454951 @default.
• W4379281330 hasConceptScore W4379281330C104317684 @default.
• W4379281330 hasConceptScore W4379281330C121608353 @default.
• W4379281330 hasConceptScore W4379281330C126322002 @default.
• W4379281330 hasConceptScore W4379281330C143998085 @default.
• W4379281330 hasConceptScore W4379281330C182979987 @default.
• W4379281330 hasConceptScore W4379281330C2779138821 @default.
• W4379281330 hasConceptScore W4379281330C2780194787 @default.
• W4379281330 hasConceptScore W4379281330C2780427987 @default.
• W4379281330 hasConceptScore W4379281330C2781179581 @default.
• W4379281330 hasConceptScore W4379281330C2908647359 @default.
• W4379281330 hasConceptScore W4379281330C50382708 @default.
• W4379281330 hasConceptScore W4379281330C530470458 @default.
• W4379281330 hasConceptScore W4379281330C54355233 @default.
• W4379281330 hasConceptScore W4379281330C71924100 @default.
• W4379281330 hasConceptScore W4379281330C82381507 @default.
• W4379281330 hasConceptScore W4379281330C86803240 @default.
• W4379281330 hasConceptScore W4379281330C99454951 @default.
• W4379281330 hasIssue "16_suppl" @default.
• W4379281330 hasLocation W43792813301 @default.
• W4379281330 hasOpenAccess W4379281330 @default.
• W4379281330 hasPrimaryLocation W43792813301 @default.
• W4379281330 hasRelatedWork W1497786936 @default.
• W4379281330 hasRelatedWork W2023425329 @default.
• W4379281330 hasRelatedWork W2064686480 @default.
• W4379281330 hasRelatedWork W2095345972 @default.
• W4379281330 hasRelatedWork W2150111967 @default.
• W4379281330 hasRelatedWork W2155077382 @default.
• W4379281330 hasRelatedWork W2166734873 @default.
• W4379281330 hasRelatedWork W2402528160 @default.
• W4379281330 hasRelatedWork W2416653885 @default.
• W4379281330 hasRelatedWork W4313005602 @default.
• W4379281330 hasVolume "41" @default.
• W4379281330 isParatext "false" @default.
• W4379281330 isRetracted "false" @default.
• W4379281330 workType "article" @default.